RPG Life Sciences Limited — Investor Presentation 2021

Jun 14, 2021

==> picture [506 x 98] intentionally omitted <==

June 14, 2021

BSE Limited,

Corporate Service Department, 1[st] Floor, P.J. Towers, Dalal Street, Mumbai 400 001

The National Stock Exchange of India Limited, Exchange Plaza, 3[rd] Floor, Plot No. C/1, “G” Block, Bandra Kurla Complex, Bandra East, Mumbai 400 051

Script Code: 532983

Symbol: RPGLIFE

Sub: Investors Presentation

Dear Sir/Madam,

In continuation to our letter dated June 9, 2021, please find enclosed herewith the Investors’ Presentation which will be made during RPG Annual Investor Conference 2021.

Kindly take the same on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited Rajesh Shirambekar Encl.: as above

==> picture [67 x 69] intentionally omitted <==

==> picture [531 x 56] intentionally omitted <==

==> picture [245 x 309] intentionally omitted <==

Investors’ Presentation

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences Overview

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.

Domestic Formulations

Develop, manufacture and market branded formulations in India & Nepal

APIs 17% International Formulations Domestic International Develop, manufacture and sell oral solid dosage Formulations Formulations formulations in the generics and branded (DF) 62% (IF) 21% generics space across Regulated and Emerging Markets

APIs Develop, manufacture and sell high value synthetic APIs in the general therapeutic category

==> picture [149 x 17] intentionally omitted <==

==> picture [74 x 55] intentionally omitted <==

==> picture [71 x 70] intentionally omitted <==

==> picture [73 x 49] intentionally omitted <==

==> picture [74 x 57] intentionally omitted <==

==> picture [75 x 51] intentionally omitted <==

Leader in Immunosuppressants

6 Leading Text Book Brands

50+ Markets Presence

3 Manufacturing Facilities

1100+ Employees

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences Product Portfolio

Domestic Formulations

Key Products

Key Therapies

==> picture [748 x 223] intentionally omitted <==

----- Start of picture text -----

Immunosuppressant Portfolio Text Book Brands New Portfolio
• Specialty Chronic
Nephrology
Azathioprine
•
Rheumatology
Azathioprine
• Trastuzumab
Oncology Spironolactone
• Orthopaedics Vildagliptin
Adalimumab
• Gastroenterology Mycophenolate Mofetil Diphenoxylate HCl
•
Cardiology Bevacizumab
• Diabetology Cyclosporine Naproxen Teneligliptin
• Neuropsychiatry Haloperidol Rituximab
Tacrolimus
Disopyramide Phosphate Tofacitinib
----- End of picture text -----

International Formulations

Key Products

Generics - Azathioprine, Sodium Valproate PR, Nicorandil Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune, Dipsope

Key Products

APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate

==> picture [131 x 52] intentionally omitted <==

==> picture [149 x 17] intentionally omitted <==

APIs

Key Financials, Business Highlights & Strategy

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Key Financial Highlights

(All figures in Rs. Crores except EPS in Rs.)

==> picture [943 x 398] intentionally omitted <==

----- Start of picture text -----

Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin
389.1 70.8 53.6
375.6 59.9
41.8
34.4
330.2 15.1
10% 16% 18% 5% 11% 14%
FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21
PAT & PAT Margin EPS
40.0 24.2
29 17.5
10.8
6.5
3% 8% 10%
----- End of picture text -----

==> picture [253 x 184] intentionally omitted <==

----- Start of picture text -----

PAT & PAT Margin
40.0
29
10.8
3% 8% 10%
FY19 FY20 FY21
----- End of picture text -----

==> picture [279 x 189] intentionally omitted <==

----- Start of picture text -----

EPS
24.2
17.5
6.5
FY19 FY20 FY21
----- End of picture text -----

==> picture [149 x 17] intentionally omitted <==

Key Financial Highlights : Balance Sheet Ratios

==> picture [904 x 247] intentionally omitted <==

----- Start of picture text -----

ROCE% ROE% Debt/Equity Ratio
18.5% 0.22
23.6% 24.3% 16.4%
11.0%
6.7%
0.06
0.01
FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21
----- End of picture text -----

==> picture [149 x 17] intentionally omitted <==

==> picture [463 x 59] intentionally omitted <==

----- Start of picture text -----

Company becomes Debt-free
----- End of picture text -----

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences ICRA Rating Upgradation

Long term rating upgraded to A from A- Short term rating upgraded to A1 from A2+

Outlook on long term rating has been retained as Stable.

The rating upgradation factors:

• ➢ Considerable improvement in the operating performance on the back of

• Improvement in sales hygiene

• Cost rationalisation measures adopted over FY2020 and H1 FY2021.

• ➢ A robust capital structure and strong coverage indicators based on

• Decline in the company’s debt levels

• Healthy cash flows

• No major debt-funded capital expenditure (capex)

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Business Segment-wise Performance

• Domestic Formulations contributed 62% to total Sales of FY21 • Sustained sales with +ve growth despite Covid headwinds : Deeper Acute Portfolio deceleration, Transplant, Dialysis centres/Clinics closure, smaller companies worse hit etc • Product Portfolio rejuvenation - New launches in specialty (Biosimilars) and chronic (Gliptins) segments • Building Strategic Brand Assets - Life Cycle Management Initiatives (New Line Extensions; New customer segments ) • API contributed 17% to total Sales of FY21 • Covid impacted the demand of our acute portfolio. However thrust on new customer development helped us to prevent sales erosion • International Formulations contributed 21% to total Sales of FY21 • UKMHRA approval of our Complex Generic Product Sodium Valproate PR; launched in UK • Growth driven by regulated markets. Myanmar, one of our key emerging markets, faced disruptions due to political instability

195.8 240.5 242.1 FY19 FY20 FY21 67.1 69.7 80.2 FY19 FY20 FY21 68.2 67.4 67.9 FY19 FY20 FY21 Net Sales (Rs Crs)

• Domestic Formulations contributed 62% to total Sales of FY21

• • Sustained sales with +ve growth despite Covid headwinds : Deeper Acute

• Domestic Portfolio deceleration, Transplant, Dialysis centres/Clinics closure, smaller

• Formulations companies worse hit etc • Product Portfolio rejuvenation - New launches in specialty (Biosimilars)

• (DF) and chronic (Gliptins) segments

• • Building Strategic Brand Assets - Life Cycle Management Initiatives (New Line Extensions; New customer segments )

• International Formulations contributed 21% to total Sales of FY21

• •

• International UKMHRA approval of our Complex Generic Product Sodium Valproate PR; launched in UK

• Formulations (IF) • Growth driven by regulated markets. Myanmar, one of our key emerging markets, faced disruptions due to political instability

  • API contributed 17% to total Sales of FY21

  • •

  • API Covid impacted the demand of our acute portfolio. However thrust on new customer development helped us to prevent sales erosion

==> picture [149 x 17] intentionally omitted <==

Domestic Formulations

Highlights

• Operating in Mass/Mass-specialty and Specialty segments

• Presence in both Acute & Chronic therapy areas

• Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace

• Leader in Immunosuppressant category

• Good Customer Coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists

• New Product Launches in New Category – Biosimilars

Business Strategy

==> picture [942 x 217] intentionally omitted <==

----- Start of picture text -----

5 Pillars of Profitable Domestic Business Growth
1 2 3 4 5
Product Portfolio Strategic Brand Assets Customer coverage Sales force Profitability
Rejuvenation by building through Life deepening in targeted effectiveness improvement by Opex
building Chronic & Cycle Management by therapies by expanding augmentation by control, efficient
Specialty Portfolio with introducing Line field force and deploying competencies building manufacturing
New Launches Extensions digital and productivity operations and sales
enhancement initiatives hygiene
----- End of picture text -----

International Formulations

Highlights

• Strong presence in immunosuppressant segment (Azathioprine)

• Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa

• Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world

• High Quality and Process orientation making us a preferred partner

Business Strategy

==> picture [149 x 17] intentionally omitted <==

==> picture [634 x 200] intentionally omitted <==

----- Start of picture text -----

3 Pillars of Step-wise Global Business build up
1 2 3
Build Focus on products with specific/ Expand footprints in
Immunosuppressant competitive advantage e.g. Nicorandil Emerging Markets like
Portfolio (Special manufacturing conditions like Myanmar, Vietnam,
low RH), Sodium Valproate PR Philippines, Sri Lanka,
(Complex Generic product) Egypt, Sudan
----- End of picture text -----

==> picture [131 x 52] intentionally omitted <==

APIs

Highlights

• High Value, Low Volume Niche APIs

• Mature Stable Molecules

• Provides backward integration to International Formulations business

• Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc

• Strong customer focus - Long lasting relationship with Big Pharma and Leading Generic Firms.

Business Strategy

==> picture [149 x 17] intentionally omitted <==

==> picture [548 x 246] intentionally omitted <==

----- Start of picture text -----

Business Continuity
1 2 3
Efficiency enhancement Niche Product Focus - Mature Stable Molecules
Quinfamide – Market/Customer
Expansion
----- End of picture text -----

==> picture [131 x 52] intentionally omitted <==

Infrastructure & Backend Capabilities

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Manufacturing Facilities

Formulations Unit 1, Ankleshwar

• F1 unit caters to the Domestic and Emerging Markets

• Multipurpose plant with dedicated product lines for Oral Dosage forms including Tablets, Liquids and Powder

• WHO, Kenya, Nigeria approved

Formulations Unit 2, Ankleshwar

• F2 unit caters to the Regulated Markets

• Dedicated product lines for Oral Dosage

• Equipped to handle low RH and low temperature conditions products

• WHO, EUGMP, Canada, Ethiopia, Kenya, Sudan, Nigeria approved

API Unit, Navi Mumbai

• MF1: Multipurpose unit catering to emerging markets including India

• MF2: Dedicated Immunosuppressant facility catering to Regulated markets

• MF3: Multipurpose unit catering to Regulated markets

• WHO, TGA Australia approved

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Strong Backend Capabilities

==> picture [58 x 59] intentionally omitted <==

Quality

• All Critical SOPs harmonized through CQA

• Quarterly Internal audit of all plants by CQA

• All critical deviations, change controls and market complaints investigation approved by CQA

==> picture [60 x 60] intentionally omitted <==

Formulations R&D

• In addition to Formulations Development of IR, have capabilities to develop Modified Release & Complex Generics

• Dossiers Gap Analysis and fulfilment

• Tech Transfer/Site transfer activities

• GLP compliant Analytical Lab for Development and Validation of Analytical Methods

==> picture [149 x 17] intentionally omitted <==

==> picture [59 x 60] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Regulatory

• Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and Emerging markets

• • Expertise of eCTD submissions

• Integrated Project Management activities

==> picture [56 x 56] intentionally omitted <==

Digitization Focus Areas

• Quality Management systems : e-QMS, e-DMS, e-LMS .

• Access to critical manufacturing equipment through IRIS

scanner

• All QC instruments attached with dedicated software and server

• All stability chambers with software control

• Secondary packing Complies with EUFMD requirement for Track and Trace.

==> picture [131 x 52] intentionally omitted <==

Operational Highlights

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences response to COVID-19

A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our Plants did not stop even for a single day. Every patient, who asked for our critical medicines, serviced by door delivery.

Key Priorities

==> picture [40 x 43] intentionally omitted <==

Employees Care

• Strict protective measures across all locations

• Detailed SOP

• Immunity boosting measures

• Special Care for co-morbidities

• Enhanced medical Insurance

• Advisories/Sessions

• PPE kits, Masks and Sanitizers

==> picture [49 x 49] intentionally omitted <==

Business Continuity

Conserve Cash

• Sustained OPEX control measures

• Company became debt-free

Supply Continuity

• RM/PM availability through proactive planning and relationship management with key vendors

==> picture [48 x 48] intentionally omitted <==

Community Service

• “SafeSeniors” tool development for early detection of risk in vulnerable Senior citizen segment

• Community Servicing through RPG Foundation - sanitizers, masks, gloves, PPE Kits; meals, etc.

Customer Outreach through Digital

• Continuous Digital Connect/Engagement with employees and their families

==> picture [149 x 17] intentionally omitted <==

• Deployment of Digital initiatives like e-CMEs, teleconsultation facilitation service, webinars, etc.

==> picture [131 x 52] intentionally omitted <==

New Digitalization Initiatives to Transform Business

Game Changer Customer Connect Initiative

==> picture [122 x 68] intentionally omitted <==

==> picture [161 x 318] intentionally omitted <==

==> picture [99 x 54] intentionally omitted <==

Anytime, Anywhere Doctor Support Initiative Industry First Initiative

==> picture [98 x 53] intentionally omitted <==

==> picture [85 x 56] intentionally omitted <==

==> picture [85 x 52] intentionally omitted <==

==> picture [98 x 53] intentionally omitted <==

Range of Services >8000 Key Opinion Leaders

==> picture [98 x 53] intentionally omitted <==

Employee Connect Initiatives

Digital Platform for comprehensive Salesforce Operations tracking : #Customer visits, customer engagement activities, sales performance analytics etc

==> picture [87 x 20] intentionally omitted <==

==> picture [83 x 76] intentionally omitted <==

HR Chatbot for quick resolution of queries related to HR process and company policies

==> picture [71 x 39] intentionally omitted <==

A digital platform for Salesforce Grievance Redressal

Initiatives in Plant Operations

e-QMS : Digital Platform to track all 6 Quality parameters e-DMS : Digital Platform to manage all manufacturing/quality documents

e-LMS : Digital Platform to Track Training Sessions on CGMP e- Access : Retina Scanning for machine access

All above represent Illustrative list of the initiatives

==> picture [149 x 17] intentionally omitted <==

People Initiatives to build Performance Culture with focus on Happiness

==> picture [118 x 17] intentionally omitted <==

----- Start of picture text -----

I Love My Work
----- End of picture text -----

==> picture [531 x 229] intentionally omitted <==

----- Start of picture text -----

I Feel Valued
RPGLS Heroes
Outperformance
Recognition
You Excel. We Applaud.
Motivation Continuum
Signature
People Initiatives
I Live a Purposeful &
Balanced Life
----- End of picture text -----

==> picture [158 x 35] intentionally omitted <==

----- Start of picture text -----

I Live a Purposeful &
Balanced Life
----- End of picture text -----

==> picture [228 x 113] intentionally omitted <==

----- Start of picture text -----

RPGLS Values
Champions
Living Organizational
Values
----- End of picture text -----

==> picture [236 x 133] intentionally omitted <==

----- Start of picture text -----

I Feel Connected
RPGLS Happiness
Forums
Leadership Connect –
Month & Quarter
----- End of picture text -----

==> picture [149 x 17] intentionally omitted <==

I am Growing

==> picture [233 x 144] intentionally omitted <==

----- Start of picture text -----

We Skill. You Grow.
Competency Building
Continuum
Akanksha
Career Development
----- End of picture text -----

I cherish our Culture

==> picture [233 x 112] intentionally omitted <==

----- Start of picture text -----

RPGLS Parivar
Tyohar-Utsav
Shrankhla
Digital RPGLS Family
Get Together
----- End of picture text -----

==> picture [131 x 52] intentionally omitted <==

Awards & Recognitions

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences Bagged Top Awards from IDMA

Prestigious Awards from IDMA - Indian Drug Manufacturer’s Association in January 2020 (consists of 1000+ pharma companies)

==> picture [286 x 197] intentionally omitted <==

IDMA Quality Excellence Award 2019 (GOLD AWARD)

==> picture [149 x 17] intentionally omitted <==

==> picture [292 x 200] intentionally omitted <==

IDMA Margi Patel Choksi Memorial Best Patent Award 2019

==> picture [292 x 200] intentionally omitted <==

IDMA Corporate Citizen Award 2019

==> picture [131 x 52] intentionally omitted <==

RPG Life Sciences is one of the India’s Best Workplace in 2020 – Amongst Top 100

==> picture [86 x 130] intentionally omitted <==

• Ranked 85 amongst India's 100 Best Companies to Work For 2020

• One of India's Best Workplaces in Biotechnology & Pharmaceuticals ​by Great Place to Work® Institute ​

==> picture [364 x 257] intentionally omitted <==

==> picture [149 x 17] intentionally omitted <==

==> picture [365 x 257] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

Media Recognition

• Not a single day Plant stoppage

• Home Delivery of critical life saving medicines to all the patients

==> picture [437 x 300] intentionally omitted <==

==> picture [511 x 305] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==

==> picture [149 x 17] intentionally omitted <==

T H A N K Y O U

==> picture [149 x 17] intentionally omitted <==

==> picture [131 x 52] intentionally omitted <==